-transparent.png){kind=logo}
CSF somatostatin and homovanillic acid (HVA) were measured in 14 schizophrenic patients while they were drug-free and during chronic fluphenazine treatment. CSF somatostatin was significantly reduced and CSF HVA was significantly elevated (p less than 0.002) during fluphenazine treatment. There was a trend toward correlation between CSF somatostatin and CSF HVA in the 14 schizophrenic patients when drug-free (r = 0.49, p less than 0.07) and fluphenazine-treated (r = 0.47, p less than 0.08). When examined in a larger group (n = 46) of drug-free schizophrenics, this relationship was highly significant (r = 0.59, p less than 0.001). These clinical data are consistent with preclinical evidence indicating a functional interaction between CNS somatostatin and dopamine systems.
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
March 1966,
Acta neurologica et psychiatrica Belgica,
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
January 1985,
Psychopharmacology,
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
May 1966,
Annales medico-psychologiques,
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
March 1962,
Diseases of the nervous system,
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
January 1992,
Biological psychiatry,
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
April 1987,
Biological psychiatry,
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
August 1974,
Activitas nervosa superior,
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
April 1989,
Psychiatry research,
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
June 1979,
Neurology,
A R Doran, and
D R Rubinow, and
O M Wolkowitz, and
A Roy, and
A Breier, and
D Pickar
September 1994,
Biological psychiatry,
